Responses to faecal microbiota transplantation in female and male patients with irritable bowel syndrome

Table 1 Characteristics of the patients in the placebo and active treated groups

	Placebo			P value	Active treated			P value
	Total	Females	Males		Total	Females	Males
n	55	47	8		109	85	24
Age, yr (median, range)	38.5 (18-75)	38.0 (18-73)	47.0 (20-75)	0.3	39.0 (18-73)	40.0 (18-73)	32.0 (21-65)	0.07
IBS-D	21	19	2	0.7	42	30	12	0.4
IBS-C	22	18	4		40	32	8
IBS-M	12	10	2		27	23	4
IBS duration, yr	15.5 ± 7.9	16.2 ± 8.0	15.0 ± 9.0	0.9	17.3 ± 8.9	16.8 ± 8.2	18.0 ± 9.2	0.9
Age at IBS onset, yr (median, range)	20.0 (15-35)	20.5 (16-35)	19.0 (15-30)	0.4	20.0 (15-36)	20.0 (16-35)	20 (15-33)	0.6
IBS-SSS total score	315.2 ± 77.1	320.1 ± 77.8	286.9 ± 69.3	0.5	312.9 ± 82.0	319.1 ± 77.3	297.7 ± 82.0	0.4
Moderate symptoms1 (%)	23 (42)	17 (36)	6 (75)	0.06	45 (41)	30 (35)	13 (54)	0.1
Severe symptoms2 (%)	32 (58)	30 (64)	2 (25)		64 (59)	55 (65)	11 (46)

Data are n, n (%) or mean ± SD values.

¹Irritable bowel syndrome severity scoring system total score between 175 and 300.

²Irritable bowel syndrome severity scoring system total score of ≥ 300. IBS: Irritable bowel syndrome; IBS-D: Irritable bowel syndrome with diarrhoea-predominant; IBS-C: Irritable bowel syndrome with constipation-predominant; IBS-M: Irritable bowel syndrome with mixed diarrhoea and constipation; IBS-SSS: Irritable bowel syndrome severity scoring system.